Date on Master's Thesis/Doctoral Dissertation
12-2019
Document Type
Master's Thesis
Degree Name
M.S.
Department
Pharmacology and Toxicology
Degree Program
Pharmacology and Toxicology, MS
Committee Chair
Siskind, Leah
Committee Co-Chair (if applicable)
Beverly, Levi
Committee Member
Beverly, Levi
Committee Member
Clark, Geoff
Committee Member
Lederer, Eleanor
Committee Member
Yaddanapudi, Kavitha
Author's Keywords
Cisplatin; neutral ceramidase; acute kidney injury; chronic kidney disease
Abstract
Cisplatin is a commonly used chemotherapeutic agent with a dose-limiting nephrotoxicity. 30% of patients given cisplatin develop acute kidney injury (AKI). AKI increases risk of chronic kidney disease (CKD) development and mortality. Patients that don’t develop clinical AKI are still at risk for long term declines in renal function. Currently, there are no FDA approved agents to treat or prevent cisplatin-induced kidney injury (CDDP-KI). In this study, we demonstrated that neutral ceramidase (nCDase) knockout provides protection from AKI in the high-dose model of CDDP-KI. However, in the repeated low dose cisplatin (RLDC) model of injury and we found nCDase knockout does not prevent development of CKD. We also observed that nCDase knockout reduces induction of ER stress in the single high-dose model but not in the RLDC model. This study suggests there are unique mechanisms of RLDC induced kidney injury which may have hindered development of nephroprotective agents.
Recommended Citation
Sears, Sophia M., "Characterizing the roles of neutral ceramidase in cisplatin-induced kidney injury." (2019). Electronic Theses and Dissertations. Paper 3396.
https://doi.org/10.18297/etd/3396